Medline (NASDAQ:MDLN) Receives $50.85 Average Target Price from Analysts

Medline (NASDAQ:MDLN) has been given a consensus recommendation of “Moderate Buy” by the twenty-nine brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, twenty-one have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $50.8462.

MDLN has been the topic of a number of recent analyst reports. BMO Capital Markets lifted their price target on Medline from $45.00 to $54.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Tigress Financial lifted their price target on Medline from $60.00 to $62.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Sanford C. Bernstein dropped their price target on Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Royal Bank Of Canada lifted their price target on Medline from $47.00 to $53.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Finally, Stifel Nicolaus set a $55.00 price target on Medline in a report on Wednesday, February 25th.

Medline Stock Performance

Shares of Medline stock opened at $37.01 on Friday. The stock’s fifty day simple moving average is $42.82. Medline has a 12 month low of $34.89 and a 12 month high of $50.88.

Medline (NASDAQ:MDLN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04. The business had revenue of $7.35 billion for the quarter. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. Research analysts anticipate that Medline will post 1.5 EPS for the current year.

Institutional Trading of Medline

Several hedge funds have recently made changes to their positions in the company. North Star Investment Management Corp. raised its stake in shares of Medline by 60.2% in the first quarter. North Star Investment Management Corp. now owns 1,362 shares of the company’s stock valued at $61,000 after buying an additional 512 shares during the period. Sound Income Strategies LLC bought a new stake in shares of Medline in the fourth quarter valued at $25,000. Entrust Financial LLC bought a new stake in shares of Medline in the fourth quarter valued at $26,000. NBC Securities Inc. bought a new stake in shares of Medline in the fourth quarter valued at $28,000. Finally, Whipplewood Advisors LLC bought a new stake in shares of Medline in the first quarter valued at $30,000.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.